You are here

A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center
Bakersfield, California, 93309 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Solid Tumor
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. At least 18 years of age and willing and able to provide informed consent.

2. Histologically or cytologically confirmed advanced solid tumor with no available
standard treatment options in the opinion of the investigator.

3. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.

4. Estimated life expectancy of ≥ 3 months.

5. Able to swallow the study drug, have no known intolerance to the study drug or
excipients, and comply with study requirements.

6. Female patients of childbearing potential must have a negative pregnancy test at
screening and must agree to use a highly effective birth control method from the time
of the first dose of study drug through 45 days after last dose of study drug.

7. Male patients must use a condom when having sex with a pregnant woman or with a woman
of childbearing potential from the time of the first dose of study drug through 105
days after last dose of study drug. Contraception should be considered for a
nonpregnant female partner of childbearing potential.

8. Male and female patients must agree not to donate sperm or eggs, respectively, from
the first dose of study drug through 105 days and 45 days after the last dose of study
drug, respectively.

9. Female patients may not be breastfeeding at screening and must not breastfeed during
study participation through 45 days after the last dose of study drug.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Use of antineoplastic therapies within 21 days before day 1.

2. Use of any other investigational agent within 21 days before day 1.

3. Have not recovered (recovery is defined as National Cancer Institute Common
Terminology Criteria for Adverse Events [CTCAE] grade ? 1) from the acute toxicities
of previous therapy, except treatment related alopecia or laboratory abnormalities
otherwise meeting eligibility requirements.

4. Electrolyte abnormality that has not responded to correction, including hypokalemia or
hypocalcemia less than the lower limit of normal, or hyperkalemia or hypercalcemia
greater than the upper limit of normal (ULN).

5. Major surgery within 14 days before day 1.

6. Diagnosis of myelodysplastic syndrome (MDS) or a hematologic malignancy.

7. Clinically significant cardiovascular disease.

8. Significant organ dysfunction.

9. Gastrointestinal disorder affecting absorption.

10. Current or anticipated use of a strong P-gp inhibitor, strong P-gp inducer, or strong
inhibitor of BCRP.

11. Any condition (concurrent disease, infection, or comorbidity) that interferes with
ability to participate in the study, causes undue risk, or complicates the
interpretation of safety data, in the opinion of the investigator or medical monitor.

NCT03042910
Pfizer
Completed
A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Solid Tumors, Ewing Sarcoma, Rhabdoid Tumor, Rhabdomyosarcoma, Neuroblastoma, Medulloblastoma
NCT03709680
All Genders
Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
NCT03330405
All Genders
18+
Years
Multiple Sites
Locally Advanced or Metastatic Solid Tumors, BRCA 1 Genes
NCT03565991
All Genders
18+
Years
Multiple Sites
Advanced Solid Tumors, Metastatic Solid Tumors
NCT03854227
All Genders
18+
Years
San Antonio, Texas

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now